Journal article
Managing atypical hemolytic uremic syndrome: chapter 2
Kidney international, Vol.87(5), pp.882-884
05/2015
DOI: 10.1038/ki.2015.60
PMID: 25951068
Abstract
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.
Details
- Title: Subtitle
- Managing atypical hemolytic uremic syndrome: chapter 2
- Creators
- Carla M Nester - Stead Family Department of Pediatrics, University of Iowa, Iowa City, USA
- Resource Type
- Journal article
- Publication Details
- Kidney international, Vol.87(5), pp.882-884
- Publisher
- Elsevier Inc
- DOI
- 10.1038/ki.2015.60
- PMID
- 25951068
- ISSN
- 0085-2538
- eISSN
- 1523-1755
- Language
- English
- Date published
- 05/2015
- Academic Unit
- Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Internal Medicine
- Record Identifier
- 9984093500502771
Metrics
21 Record Views